Eli Lilly, weight loss
Digest more
Eli Lilly (NYSE:LLY) is growing like a software company. Q1 2026 revenue hit $19.80B, up 55.5% year over year, with Mounjaro ...
A new study shows those who took retatrutide lost a whopping 28% of their body weight after 80 weeks, similar to weight loss ...
Eli Lilly said its retatrutide cleared a late-stage trial in patients with obesity, with some of them shedding a third of ...
Pharmaceutical Technology on MSN
Eli Lilly maintains M&A streak with $202m Engage Bio buyout
Lilly’s takeover of Engage Bio marks the seventh acquisition for the big pharma since the start of 2026.
A web of mail-order pharmacies, wholesalers and patient services groups connected to the self-styled largest Pentecostal ...
The GLP-1 agonists weight loss drugs market offers growth potential through rising obesity rates, innovative drug approvals, ...
The US Supreme Court said Monday it won’t review Eli Lilly and Co.'s challenge to a $193 million Medicaid drug fraud judgment in a whistleblower’s False Claims Act suit.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results